REG - Sareum Holdings PLC - AGM Update

Sareum HoldingsAnnouncement

07/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211207:nRSG7480Ua&default-theme=true

RNS Number : 7480U  Sareum Holdings PLC  07 December 2021

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Update on AGM

Cambridge, UK, 07 December 2021 - Sareum Holdings plc (AIM: SAR), the
specialist small molecule drug development business, provides an update on its
Annual General Meeting ("AGM") in response to the recent emergence of the
omicron variant of the SARS-CoV-2 virus. In addition to the planned in-person
meeting at 10.00 a.m. on 16 December 2021 at The City Centre, 80 Basinghall
Street, London EC2V 5AG, the AGM will now also be relayed as a live webcast
via the Investor Meet Company (IMC) platform.

Shareholders attending in-person and via the IMC platform will be able to
raise questions with the Board of Directors in a Q&A session to be held
immediately after the AGM.

As an added precaution to ensure the safety of in-person attendees, the AGM
will conclude immediately following the Q&A session.

Shareholders are reminded that participation via the IMC platform will not
constitute attendance at the AGM and those shareholders following the meeting
via the IMC platform will not be able to vote on the day of the AGM - details
on how to vote online are set out below.

Shareholders wishing to join the AGM remotely and participate in the Q&A
session should register with IMC at:
www.investormeetcompany.com/sareum-holdings-plc/register-investor
(https://www.investormeetcompany.com/sareum-holdings-plc/register-investor) .
Shareholders who have already registered with IMC and requested to meet the
Company will be invited automatically.

Questions can be submitted before the event via the IMC dashboard or at any
time during the AGM via the "Ask a Question" function. Although the Company
may not be able to answer every question it receives, it will seek to address
the most prominent questions within the confines of information already
disclosed to the market. Responses from the Q&A session will be published
at the earliest opportunity on the IMC platform.

Voting

Shareholders are encouraged to vote electronically and to appoint the Chair of
the AGM as their proxy.

Shareholders are requested to submit their votes online, no less than 48 hours
before the time appointed for the meeting, via the shareholder portal at
www.signalshares.com (http://www.signalshares.com/) , where details of the
procedures are set out. If shareholders have not done so already, they will
need to register their account using their Investor Code, which can be found
on their share certificate.

If shareholders hold shares in CREST and wish to vote via Signal Shares rather
than the CREST electronic proxy appointment services, please contact the
Company's registrars, Link Asset Services, to obtain their investor code.

Alternatively, shareholders may request a paper form of proxy from the
Company's registrars, Link Asset Services, and details of how to contact them
are set out in the Notice of AGM.

In order to vote online, shareholders will need to visit www.signalshares.com
(http://www.signalshares.com) , search 'Sareum Holdings Plc' and use their
Investor Code to log in or register. Once logged in, click the 'Vote Online
Now' button and follow the procedure as instructed.

Posting of the Annual Report and Accounts and Notice of AGM

The Notice of AGM, along with a copy of the Company's Annual Report and
Accounts for the year ended 30 June 2021, were posted on 19 November 2021 to
those shareholders who requested a hard copy. A copy of both documents is
available on the Company's website www.sareum.com (http://www.sareum.com) .

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                          01223 497 700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel                                020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                               020 3764 2341

 MEDiSTRAVA Consulting (Financial PR)

 Mark Swallow / David Dible                 020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.

SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPAKELNFFFA